Amphastar Pharmaceuticals, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a biopharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products; complex medications including biologics, proteins, and interchangeable biosimilars; innovative drug delivery systems; and insulin active pharmaceutical ingredients such as recombinant human insulin and porcine insulin. Its marketed products include BAQSIMI (glucagon nasal powder 3mg), Primatene MIST (epinephrine inhalation aerosol), Glucagon for Injection Emergency Kit, enoxaparin, naloxone, Cortrosyn (cosyntropin for injection), Amphadase, epinephrine injection, lidocaine jelly and topical solution, phytonadione injection, and others primarily used in hospital, urgent care, and retail pharmacy settings. Founded in 1996 and headquartered in Rancho Cucamonga, California, the company operates manufacturing facilities in the United States, China, and France, with all finished products produced domestically; it targets healthcare providers through group purchasing organizations and drug wholesalers, maintaining a presence in the United States, Asia, and Europe. In August 2025, Amphastar entered an exclusive licensing agreement with Nanjing Anji Biotechnology Co., Ltd. for three proprietary peptides in the US and Canada—an endogenous peptide for poorly treated cancers, a peptide-docetaxel conjugate to enhance taxane therapies, and an anti-VEGFR peptide eye drop for wet age-related macular degeneration—with upfront payments of $6 million and potential milestones up to $453 million. The company announced in July 2025 a multi-year expansion to quadruple domestic production capacity at its Rancho Cucamonga headquarters over three to five years, including a new state-of-the-art facility, advanced automation, and job creation in R&D, engineering, manufacturing, and quality; its subsidiary International Medication Systems, Ltd. received the FDA's Drug Shortage Assistance Award for efforts in addressing critical shortages.
Company News
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript
Amphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Amphastar Pharmaceuticals Q3 Earnings Call Highlights
Amphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Rating of “Reduce” from Analysts
Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $239,400.00 in Stock
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
New Strong Sell Stocks for August 14th
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply